Enfumafungin is primarily studied for its antifungal properties, making it a potential candidate for treating fungal infections. It works by inhibiting the synthesis of β-glucan, a crucial component of fungal cell walls, which leads to the weakening and eventual death of the fungus. This mechanism is particularly effective against Candida species, including drug-resistant strains, making it a promising option for developing new antifungal therapies. Research is ongoing to explore its efficacy in clinical settings, especially for patients with compromised immune systems who are more susceptible to severe fungal infections. Additionally, its unique action mechanism may help reduce the risk of cross-resistance with existing antifungal drugs.